Cannabidiol is a compound obtained from cannabis which has reduced seizures in some children with epilepsy, as indicated by a controlled study released in May 2017 in the New England Journal of Medicine. The journal was supported by GW Pharmaceuticals and is primarily a thorough investigation to show that cannabis components can effectively treat such seizures.
Cannabidiol isn’t psychoactive and in this way does not influence perception or make people high. Parents have been utilizing it to treat their children’s seizures and have noticed its effectiveness.
The study involved 120 children ages 2 to 18 with Dravet syndrome — a hereditary disorder that shows itself in early youth and results in successive, drawn-out seizures and stunted development. Kids were separated into two groups and were given either cannabidiol or a placebo for 14 weeks. Cannabidiol diminished the average number of seizures that kids experienced every month by around 50 percent, while the placebo lessened average seizures by around 5 percent.
Nervous system specialist and lead author, Orrin Devinsky of New York University Langone Medical Center clearly expressed:
“We now have solid, rigorous scientific evidence that in this specific syndrome, cannabidiol is effective at reducing seizures”.
Devinsky also said that the treatment was “not a panacea.” Cannabidiol worked better than others. The said treatment was related to different symptoms including fever, drowsiness, loose bowels, and strange liver capacity, as indicated by the study.